This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
milla1cf Tue, 01/16/2024 - 13:57 January 16, 2024 — Penumbra, Inc. , Now commercially available in Europe, CAT RX is designed to navigate tortuous coronary anatomy while maintaining sustained mechanical aspiration with the Penumbra ENGINE.
Impacting 25 million people globally [1], deep venous disease results from venous thromboembolism, a condition that occurs when a bloodclot forms in the vein [2]. Deep venous anatomy and obstructions can present a multitude of complexities and mechanical challenges. It is the third most common cardiovascular disease [2].
Stroke, Volume 55, Issue Suppl_1 , Page ATP214-ATP214, February 1, 2024. Neurovascular anatomy of the virtual model was built based on digital subtraction angiography of an in-vitro model (Sim Agility, Mentice, Inc). Gravity Medical Technology’s SuperNova Stent-retriever was the device under investigation.
Patients had a valve annulus of 430 mm2 or less and anatomy suitable for either the Evolut PRO/PRO+/FX or the SAPIEN 3/3 Ultra. The trial enrolled 716 patients who underwent TAVR at 83 international sites in North America, Europe and the Middle East. of patients who received the Evolut valve and 10.6% of those receiving the SAPIEN valve.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content